SIG
TCRT icon

Sargent Investment Group’s Alaunos Therapeutics TCRT Stock Holding History

Sargent Investment Group’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-200
Closed -$55K – 199
2021
Q3 		$55K Hold
200
– – 0.01% 188
2021
Q2 		$79K Sell
200
-33
-14% -$15.4K 0.02% 197
2021
Q1 		$126K Sell
233
-357
-61% -$222K 0.03% 185
2020
Q4 		$223K Sell
590
-1,337
-69% -$532K 0.07% 160
2020
Q3 		$728K Buy
1,927
+380
+25% +$168K 0.26% 72
2020
Q2 		$759K Buy
1,547
+10
+0.7% +$4.46K 0.29% 66
2020
Q1 		$565K Sell
1,537
-167
-10% -$86.4K 0.26% 70
2019
Q4 		$1.21M Buy
1,704
+99
+6% +$68.1K 0.44% 47
2019
Q3 		$1.03M Buy
1,605
+159
+11% +$126K 0.46% 53
2019
Q2 		$1.26M Buy
1,446
+113
+8% +$77.7K 0.58% 38
2019
Q1 		$770K Buy
1,333
+73
+6% +$30.5K 0.37% 61
2018
Q4 		$353K Buy
+1,260
New +$498K 0.22% 88

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sargent Investment Group's TCRT Position: Q4 2021 in Review

Sargent Investment Group sold out of Alaunos Therapeutics (TCRT) in Q4 2021, closing a stake of 200 shares — an estimated $55K sold.

Sargent Investment Group first reported a position in TCRT in Q4 2018 and held it in 12 quarters. The position peaked at $1.26M in Q2 2019. 165 funds tracked by Wall St. Rank hold TCRT as of Q4 2021.

  • Sargent Investment Group reported no remaining Alaunos Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Sargent Investment Group sold 200 Alaunos Therapeutics shares in Q4 2021, an estimated $55K.
  • Sargent Investment Group first reported a position in Alaunos Therapeutics in Q4 2018 and held it in 12 quarters.
  • Sargent Investment Group's Alaunos Therapeutics position peaked at $1.26M in Q2 2019.
  • 165 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2021.

Based on Sargent Investment Group's 13F filing for Q4 2021, filed 11 Feb 2022.